Enzon Makes Management Changes

Ana I. Stancic, C.P.A., M.B.A., senior vice president of Finance and chief financial officer, has been promoted to chief operating officer, principal executive officer and executive vice president at Enzon. She will continue serving in her role as chief financial officer. Ralph Del Campo, M.B.A., former chief operating officer and principal executive officer, has stepped down from his position to pursue other interests.

“Enzon is focused on advancing a pipeline of novel oncology products while continuing to streamline operations and return value to its shareholders,” said Alex Denner, chairman of the board. “As the company continues to deliver on its objectives, we are confident that Ana’s experience and expertise will serve the company well in her expanded role. I would like to thank Ralph for the commitment and leadership that he has brought to Enzon during its transition from an integrated specialty pharmaceuticals company to a development-focused enterprise.”

Enzon has also formed a special committee to oversee the company’s scientific and clinical development. The committee is comprised of directors Richard A. Young, Ph.D., who will act as chairman, and Thomas F. Deuel, M.D.

Dr. Young has served as a director of Enzon since April 2010. He is a member of the Whitehead Institute and a professor of biology at the Massachusetts Institute of Technology. Dr. Deuel, a director at Enzon since April 2010, is also an adjunct professor of molecular and experimental medicine and cell biology, The Scripps Research Institute, and professor of medicine emeritus at Harvard Medical School.